Insights Into Sequencing Treatment and Overcoming Resistance in HR-Positive/HER2-Negative ABC

Get up to date on optimal management of HR-positive/HER2-negative advanced breast cancer by watching the on-demand Webcast and downloading slides from a dynamic expert presentation on current and emerging therapies targeting CDK4/6 PI3K AKT mTOR and more!

Share

Program Content

Activities

HR+/HER2- ABC: Webcast
Insights Into Sequencing Treatment and Overcoming Resistance in HR-Positive/HER2-Negative ABC
Congratulations: You achieved a completion on 04/09/2022

Activities

<i>EP:</i> HR+/HER2- ABC
ExpressPoints: Sequencing Treatment and Overcoming Resistance in HR-Positive/HER2-Negative ABC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 01, 2020

Expires: June 30, 2021

CDK4/6i for HR+/HER2- ABC
CDK4/6 Inhibitors for Premenopausal and Postmenopausal Women With HR-Positive/HER2-Negative Advanced Breast Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 17, 2020

Expires: June 16, 2021

PI3K/AKT/mTORi for ABC
PI3K/AKT/mTOR Inhibitors and Future Directions in HR+/HER2- Advanced Breast Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 17, 2020

Expires: June 16, 2021

Faculty

cover img faculity

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

cover img faculity

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Lilly